Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer
Publication
, Conference
September 9, 2023
Duke Scholars
Publication Date
September 9, 2023
Location
Singapore
Conference Name
World Conference on Lung Cancer
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Zhou, K., Lin, C., Tseng, C.-L., Ramnath, N., Dowell, J., & Kelley, M. (Eds.). (2023). Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer. Presented at the World Conference on Lung Cancer, Singapore.
Zhou, Katherine, Chenyu Lin, Chin-Lin Tseng, Nithya Ramnath, Jonathan Dowell, and Michael Kelley, eds. “Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer,” 2023.
Zhou K, Lin C, Tseng C-L, Ramnath N, Dowell J, Kelley M, editors. Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer. In 2023.
Zhou, Katherine, et al., editors. Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer. 2023.
Zhou K, Lin C, Tseng C-L, Ramnath N, Dowell J, Kelley M, editors. Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer. 2023.
Publication Date
September 9, 2023
Location
Singapore
Conference Name
World Conference on Lung Cancer
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology